» Articles » PMID: 6074002

Studies of the Metabolism and Distribution of Fibrinogen in Patients with Hemophilia A

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1967 Dec 1
PMID 6074002
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Using autologous (131)I-fibrinogen, we made studies of the metabolism and distribution of fibrinogen in 10 patients with hemophilia A. In two patients simultaneous studies of autologous (131)I-fibrinogen and homologous (125)I-fibrinogen prepared from healthy donors' plasma were carried out. The average value for the plasma volume was 42.1 +/- 8.8 ml/kg; for the plasma fibrinogen concentration, 349 +/- 90 mg/100 ml; for the intravascular fibrinogen, 144 +/- 32 mg/kg; for the interstitial fibrinogen, 30 +/- 11 mg/kg; for the slower half-life of (131)I-fibrinogen, 2.34 +/- 0.17 days; for the transcapillary transfer rate of fibrinogen, 109 +/- 37 mg/kg per day; and for the catabolic and synthetic rates of fibrinogen, 51.7 +/- 13.1 mg/kg per day. Comparison of these results with those of the previous study in healthy male subjects showed that in patients with hemophilia A the catabolic and synthetic rates of fibrinogen are markedly increased, whereas the plasma fibrinogen concentration, intravascular and interstitial fibrinogen, and the transcapillary transfer rate of fibrinogen are not significantly different. The simultaneous studies of autologous (131)I-fibrinogen and normal homologous (125)I-fibrinogen in two subjects revealed that the two preparations behaved very similarly. Based on these findings, we concluded that our present findings are not due to the qualitative difference between the hemophilia A and normal fibrinogens, but that they are due to the difference in the host condition with respect to the fibrinogen metabolism, which is either an increased rate of direct breakdown of fibrinogen or an increased rate of fibrinogen breakdown after fibrin formation, or both.

Citing Articles

CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues.

Budhu S, Loike J, Pandolfi A, Han S, Catalano G, Constantinescu A J Exp Med. 2010; 207(1):223-35.

PMID: 20065066 PMC: 2812553. DOI: 10.1084/jem.20091279.


The hemostasis system in murine atherosclerosis.

Iwaki T, Ploplis V, Castellino F Curr Drug Targets. 2008; 9(3):229-38.

PMID: 18336242 PMC: 3669676. DOI: 10.2174/138945008783755593.


Human prothrombin metabolism in normal man and in hypocoagulable subjects.

Shapiro S, Martinez J J Clin Invest. 1969; 48(7):1292-8.

PMID: 5794251 PMC: 322352. DOI: 10.1172/JCI106095.


Plasminogen- 125 I responses in dogs to a single injection of urokinase and typhoid vaccine and to vascular injury.

Takeda Y J Clin Invest. 1972; 51(6):1363-77.

PMID: 4623459 PMC: 292273. DOI: 10.1172/JCI106932.

References
1.
Takeda Y . Studies of the metabolism and distribution of fibrinogen in healthy men with autologous 125-I-labeled fibrinogen. J Clin Invest. 1966; 45(1):103-11. PMC: 292671. DOI: 10.1172/JCI105314. View

2.
Blomback B, Carlson L, Franzen S, ZETTERQVIST E . Turnover of 131-I-labelled fibrinogen in man. Studies in normal subjects, in congenital coagulation factor deficiency states, in liver cirrhosis, in polycythemia vera and in epidermolysis bullosa. Acta Med Scand. 1966; 179(5):557-74. DOI: 10.1111/j.0954-6820.1966.tb07973.x. View

3.
Cooksey M, Perry C, Raper A . Epsilon-aminocaproic acid therapy for dental extractions in haemophiliacs. Br Med J. 1966; 2(5530):1633-4. PMC: 1944488. DOI: 10.1136/bmj.2.5530.1633. View

4.
HART H . The biological half-life of I-131 fibrinogen. Thromb Diath Haemorrh Suppl. 1965; 17:121-31. View

5.
VON KAULLA K, Schultz R . Methods for the evaluation of human fibrinolysis; studies with two combined technics. Am J Clin Pathol. 1958; 29(2):104-12. DOI: 10.1093/ajcp/29.2.104. View